PDE4A and atopic eczema: Small-molecule phosphodiesterase-4 (PDE4) inhibitors, which prevent cAMP degradation, have shown efficacy across a spectrum of inflammatory diseases, including inflammatory bowel disease, atopic dermatitis, and rheumatoid arthritis [34, 35].